Hubei wallison pharmaceutical technology co., LTD. (formerly Wu Hanrui rieter biomedical technology co., LTD.), founded in early 2015, is a leading domestic pharmaceutical research and development production outsourcing organization (CDMO), mainly for domestic pharmaceutical companies, new drug research and development institutions, such as the provision from the early clinical studies until the whole life cycle of drugs listed pharmaceutical intermediates and apis needed for custom development and custom manufacturing services. Companies have adjunct professor of huazhong university of science and technology, wuhan, hubei province, a professor at the university of engineering "one hundred plan", hubei province have made outstanding contribution to the young and middle-aged experts, wuhan optical valley 3551 personnel and a group of middle-aged and young master, doctor and r&d team composed of doctoral tutor.

    The company is committed to building the world's leading pharmaceutical service platform, In Jingmen chemical recycling industrial park, a modern production workshop meeting GMP conditions is built. The new workshop can be used for hydrogenation, ammoniation, chlorination, high temperature reaction at 200 ℃ and low temperature reaction at - 78 ℃. Through five years in the field of CDMO accumulation, we have formed to provide international innovation medicine test in pharmaceutical intermediates and apis from to the core competence of commercial enlarge production services, and good certification and delivery record. Company service for the customer the product in the global annual sales income of more than $1 billion blockbuster drugs, terminal drugs involved in diabetes, fall hematic fat, resisting bacteria, and other indications. Over the years, the company adhere to the service in the field of innovative medicine, accumulated the leading r&d technology platform, perfect quality management and EHS management system, for domestic and international well-known pharmaceutical companies and drug research and development institutions to provide services.

    Current, with the domestic pharmaceutical industry policy of positive change, the development of Chinese pharmaceutical is full of new vitality, the company invested more than one hundred million yuan, actively participate in jingmen chemical recycling industrial park drug firms overall planning, support of jingmen, ecological development of the pharmaceutical industry for domestic pharmaceutical enterprises in an all-round way and drug research and development institutions provide innovation drugs and generic drugs CMC, MAH commissioned medicine production services, innovative API custom research and development and production of integrated services, gradually build up domestic leading one-stop service platform of intermediates and apis.